Four months after receiving a complete response letter from the U.S. FDA for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis, Sanofi SA received a positive opinion ...
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results